#1 Clinical Trials Search in Europe

Alfa-D-Mannopyranosyl Phosphate Dipotassium

This article discusses two clinical trials investigating the use of GLM101, a drug containing Alfa-D-Mannopyranosyl Phosphate Dipotassium, for the treatment of PMM2-CDG (Phosphomannomutase 2 – Congenital Disorder of Glycosylation). These trials aim to assess the safety, efficacy, and pharmacological properties of GLM101 in patients with this rare metabolic disorder. The studies involve both adult and pediatric participants and focus on evaluating improvements in coordination, balance, and other disease-related symptoms.

Table of Contents

What is GLM101?

GLM101 is an investigational drug being developed to treat a rare genetic disorder called PMM2-CDG. Its active ingredient is alfa-D-mannopyranosyl phosphate dipotassium, which is a form of sugar molecule enclosed in a tiny fat bubble (liposome)[1][2]. This medication is given through an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein.

Medical Condition: PMM2-CDG

PMM2-CDG stands for Phosphomannomutase 2 – Congenital Disorder of Glycosylation. It’s a rare genetic condition that affects how the body processes certain sugar molecules, leading to various health problems[1][2]. People with PMM2-CDG often have issues with coordination and balance (ataxia), as well as other metabolic and developmental problems.

How GLM101 Works

GLM101 is designed to deliver a specific sugar molecule called mannose-1-phosphate to cells in the body[1]. In people with PMM2-CDG, there’s a shortage of this sugar molecule, which is crucial for many bodily functions. By providing this missing sugar, GLM101 aims to improve the symptoms of PMM2-CDG, particularly issues with coordination and balance.

Clinical Trials

GLM101 is currently being studied in two main clinical trials:

  1. A long-term safety study for patients who have previously received GLM101[1].
  2. A 24-week study to assess how well GLM101 works and how safe it is in adults, adolescents, and children with PMM2-CDG[2].

These trials aim to understand:

  • How GLM101 affects coordination and balance (ataxia) in patients with PMM2-CDG
  • The safety and tolerability of GLM101 when given over extended periods
  • How the body processes GLM101 (pharmacokinetics)
  • Changes in certain biological markers that might indicate how well the treatment is working

Eligibility Criteria

To participate in these clinical trials, patients must meet certain criteria. Some key points include:

  • Having a confirmed diagnosis of PMM2-CDG
  • Being within specific age ranges (varies by study, but generally includes ages 2-65)
  • Not having certain other medical conditions that might interfere with the study
  • For females of childbearing potential, agreeing to use effective contraception

It’s important to note that there are additional specific criteria, and a healthcare provider or study coordinator would need to assess each potential participant individually[1][2].

Safety and Side Effects

As with any investigational drug, the full safety profile of GLM101 is still being studied. The clinical trials are closely monitoring for any side effects or adverse events. Some areas of focus include:

  • Changes in blood and urine tests
  • Effects on heart function (monitored through ECGs)
  • Changes in vital signs (blood pressure, heart rate, body temperature)
  • Any allergic reactions or hypersensitivity to the drug

Patients in the trials are carefully monitored for any unexpected side effects[1][2].

Potential Benefits

While the full effects of GLM101 are still being studied, the hope is that it may provide several benefits for people with PMM2-CDG:

  • Improved coordination and balance (reduction in ataxia)
  • Better overall function and quality of life
  • Potential improvements in other symptoms related to PMM2-CDG

It’s important to remember that as an investigational drug, the benefits of GLM101 are not yet fully proven, and more research is needed to confirm its effectiveness and safety[1][2].

Aspect Trial 2024-512171-12-00 Trial 2024-513119-29-00
Study Type Phase 2, Open-Label Extension Phase 2, Randomized, Open-Label
Duration Up to 48 months 24 weeks
Age Range 12-65 years 2-65 years (various cohorts)
Primary Objective Examine safety of GLM101 Characterize changes in ataxia
Key Secondary Objectives Examine changes in coordination and balance; Measure sugar delivery Evaluate PD activity; Assess safety and tolerability; Study PK
Drug Administration Intravenous Intravenous
Maximum Dose 30 mg/kg 30 mg/kg

FAQ

  • What is GLM101 and what is it being studied for? GLM101 is a drug containing Alfa-D-Mannopyranosyl Phosphate Dipotassium. It is being studied as a potential treatment for PMM2-CDG, a rare metabolic disorder affecting glycosylation processes in the body.
  • Who can participate in these clinical trials? The trials include participants of various age groups, from 2 to 65 years old, who have a confirmed diagnosis of PMM2-CDG. Specific eligibility criteria apply, including genetic confirmation of the disorder and meeting certain health requirements.
  • How is GLM101 administered in these trials? GLM101 is administered intravenously (through a vein) to participants. The dosage and frequency of administration may vary depending on the specific trial protocol.
  • What are the main objectives of these clinical trials? The main objectives include assessing the safety and tolerability of GLM101, evaluating its effects on coordination and balance (ataxia), measuring changes in disease-related biomarkers, and studying the pharmacokinetics of the drug in patients with PMM2-CDG.
  • How long do these clinical trials last? The duration of the trials varies. One study lasts for 24 weeks, while the other is a long-term extension study that can last up to 48 months. The exact duration may depend on the specific trial and participant group.

Ongoing Clinical Trials on Alfa-D-Mannopyranosyl Phosphate Dipotassium

  • Study on the Effects of GLM101 for Patients with PMM2-CDG

    Not recruiting

    2 1 1
    Investigated drugs:
    Spain

Glossary

  • PMM2-CDG: Phosphomannomutase 2 – Congenital Disorder of Glycosylation, a rare inherited metabolic disorder affecting the process of glycosylation, which is essential for proper protein function in the body.
  • Glycosylation: The process by which sugars are attached to proteins or other molecules in the body, crucial for many biological functions.
  • Ataxia: A neurological sign characterized by lack of voluntary coordination of muscle movements, affecting the person's ability to walk, perform fine motor tasks, or speak clearly.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Intravenous (IV): A method of administering medication or fluids directly into a vein.
  • Open-Label Study: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Biomarker: A measurable indicator of a biological state or condition, often used to assess the effectiveness of a treatment.
  • Mannose-1-Phosphate: A sugar molecule that plays a crucial role in the glycosylation process and is the active component of GLM101.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-glm101-for-patients-with-pmm2-cdg/
  2. http://clinicaltrials.eu/trial/study-on-the-effects-of-glm101-for-patients-with-pmm2-cdg/